The most commonly employed strategy for the development of therapeutic tumor vaccination banks on the formation of tumor-specific cytotoxic CD8-positive T lymphocytes, because of their unique capability to eradicate tumor cells due to specific cell recognition [16,17]. The gene discussed is CD8A; the disease is neoplasm.